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ABSTRACT 
 The objectives of this study were to investigate the clinical impact of partial volume 
effects (PVE) correction on the predictive and prognostic value of metabolically active tumor 
volume (MATV) measurements on 18F-FDG PET baseline scan for therapy response and 
overall survival in esophageal cancer patients.  
 Methods: 50 patients with esophageal cancer treated with concomitant radio-
chemotherapy between 2004 and 2008 were retrospectively considered. PET baseline scans 
were corrected for PVE with iterative deconvolution incorporating wavelet denoising. MATV 
delineation on both original and corrected images was carried out using the automatic Fuzzy 
Locally Adaptive Bayesian (FLAB) methodology. Several parameters were extracted 
considering the original and corrected images: maximum and peak SUV, mean SUV, MATV 
and TLG (TLG=MATV×mean SUV). The predictive value of each parameter with or without 
correction was investigated using Kruskal-Wallis tests and the prognostic value with Kaplan-
Meier curves. 
 Results: Whereas PVE correction had significant quantitative impact on the absolute 
values of the investigated parameters, their clinical value within the clinical context of interest 
was not significantly modified. This was observed for both overall survival and response to 
therapy. The hierarchy between parameters was the same before and after correction. SUV 
measurements (max, peak, mean) had non-significant (p>0.05) predictive or prognostic 
value, whereas functional tumor related measurements (MATV, TLG) were significant 
(p<0.002) predictors of response and independent prognostic factors. 
 Conclusions: PVE correction does not improve the predictive and prognostic value of 
baseline PET image derived parameters in esophageal cancer patients. 
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With a worldwide estimated 5-year survival of only 15% (1), esophageal cancer is the 
third most common malignancy of the digestive tract and is a leading cause of cancer 
mortality. Its incidence is still increasing and there is a growing concern regarding its 
effective management (2). Surgical resection remains the most effective treatment, 
however many patients have a locally advanced esophageal carcinoma (LAEC) at 
diagnosis and neoadjuvant therapy before surgery has demonstrated improved 
survival in this case (3). The maximum improvement in terms of increased overall 
survival from neoadjuvant treatment is observed for patients who achieve a complete 
pathological response (only 15-30% of cases) with no residual cancer cells in the 
primary tumor or lymph nodes (4). On the other hand, non responders may be 
unnecessarily affected by toxicity (5). The development of an early diagnostic test 
offering non invasive prediction of the response to therapy and/or survival is therefore 
of great interest. For tumors that cannot be surgically removed, combined radio-
chemotherapy is the preferred treatment. In this case too, early assessment of 
response to therapy would allow a modification in the management of non 
responding patients early during treatment. Such a response assessment becomes 
even more critical when one considers the availability of new targeted drugs that 
could be tested with higher efficiency if applied early (6). 
Along with Standardized Uptake Values (SUV, max or peak) usually considered in 
clinical practice, other parameters describing functional lesions, such as metabolically 
active tumor volume (MATV, defined as the tumor volume that can be seen and 
delineated on an 18F-FDG PET image) (7), mean SUV and total lesion glycolysis 
(TLG, defined as the product of MATV and its associated SUVmean) (8) have been 
investigated. The prognostic value of these parameters in esophageal cancer 
patients for overall or disease-free survival has been demonstrated (9-12). On the 
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other hand regarding therapy prediction, several studies on different cancer models 
have recently suggested using the baseline scan only, instead of the comparison of 
pre-treatment and post-treatment scans (late assessment) or during-treatment scans 
(early assessment) (13). Such investigations were for instance carried out in pleural 
mesothelioma (14), non-Hodgkin lymphoma (15) and esophageal cancer (7, 16), 
demonstrating higher statistical value for MATV-based parameters than SUV 
measurements whose predictive value has been found to be conflicting (17). 
However, in most of these studies no partial volume effects (PVE) correction (PVC) 
was applied which may explain the observed limited value of SUV. The impact of 
PVC on the clinical value of SUV measurements has been investigated by a limited 
number of authors. Hoetjes et al (18) investigated the impact of four PVC strategies 
on 15 breast cancer patients, regarding the early metabolic PET response after one 
cycle of chemotherapy. The SUV decrease between the pre-treatment scan and the 
scan early during treatment was found to be lower after PVC (26-27% vs. 31%) for 
the first three methods but not for the fourth one based on binary tumor masks (30%). 
Van Heijl et al (19) recently demonstrated a non-significant impact of PVC on the 
correlation between disease-free survival and 18F-FDG PET SUV measurements in 
52 esophageal cancer patients. In this study a PVC method based on binary tumor 
masks generated using adaptive thresholding delineation was used, while disease-
free survival was the only clinical endpoint investigated. Both the use of adaptive 
thresholding and the PVC method based on tumor masks assume a homogeneous 
tracer distribution in both tumor and background and are therefore likely to provide 
only approximate correction (20). On the other hand, no data is currently available 
regarding the impact of PVC on the value of baseline 18F-FDG PET based 
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measurements for the prediction of overall survival and response to therapy in 
esophageal cancer. 
The current study was therefore carried out to investigate the impact of an advanced 
PVC methodology and the use of an accurate MATV delineation approach on both 
the predictive and prognostic value of baseline 18F-FDG PET scan derived 
parameters.  
 
MATERIAL AND METHODS 
Patients 
50 consecutive patients with a newly diagnosed esophageal cancer were included 
and retrospectively analyzed. The characteristics of the patients are given in table 1. 
Most of them (45 out of 50) were male, aged 65±9 years at the time of diagnosis. 
74% of the tumors originated from the middle and lower esophagus and 72% were 
squamous cell carcinoma. None of the patients underwent surgery, and all were 
treated with concomitant radio-chemotherapy between 2004 and 2009. The therapy 
regime included three courses of 5-fluorouracil/cisplatin and a median radiation dose 
of 60Gy given in 180cGy daily fractions delivered once daily, 5 days a week for 6-7 
weeks. As part of the routine procedure for the initial staging in esophageal cancer, 
each patient was referred for an 18F-FDG PET study before treatment, and these 
baseline scans were used in this study.  
Overall survival was determined as the time between initial diagnosis and last follow-
up or death. Response to therapy was evaluated one month after the completion of 
the concomitant radio-chemotherapy using conventional thoraco abdominal CT and 
endoscopy. Patients were classified as non responders (NR, including stable and 
progressive disease), partial responders (PR) or complete responders (CR). 
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Response evaluation was based on CT evolution between pre-treatment and post-
treatment scans using RECIST (Response Evaluation Criteria in Solid Tumors) (21). 
Patients also underwent fibroscopy in case of partial or complete response. Complete 
response was confirmed by the absence of visible disease in the endoscopy and no 
viable tumor on biopsy. Partial CT response was confirmed by macroscopic residual 
(>10% viable) on biopsy. No discordance was observed between pathological, when 
available, and CT evaluation. The current analysis was carried out after an approval 
by the institutional ethics review board. 
18F-FDG PET acquisitions 
18F-FDG PET studies were carried out prior to the treatment. Patients were instructed 
to fast for at least 6h before a 5MBq/kg injection of 18F-FDG. Static emission images 
were acquired from head to thigh beginning 60min after injection and with 2min per 
bed position, on a Philips GEMINI PET/CT system (Philips Medical Systems, 
Cleveland, OH USA). Images were reconstructed using the RAMLA 3D algorithm 
according to standard clinical protocol: 2 iterations, relaxation parameter of 0.05, a 
5mm 3D Gaussian post-filtering, a 4x4x4mm3 voxels grid sampling, and a low dose 
CT scan-based attenuation correction. 
PET image partial volume correction and image analysis 
Images were corrected for PVE using an iterative deconvolution methodology that 
has been previously validated (22). Its principle is to iteratively estimate the inversion 
of the scanner’s Point Spread Function (PSF), which is assumed to be known and 
spatially invariant in the field of view. The considered lesions were all in the same 
body region and this approximation should therefore not have a significant impact on 
the applied correction on a patient-by-patient comparison basis. Iterative 
deconvolution methods, such as Lucy-Richardson (L-R) or Van Cittert, are known for 
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the amplification of noise associated with increasing number of iterations. To solve 
this issue, wavelet-based denoising of the residual was introduced within the iterative 
L-R deconvolution using Bayeshrink filtering (23), leading to images corrected for 
PVE without significant noise addition. The advantages of this methodology are its 
ability to generate entire whole-body corrected images independently of any manual 
or automatic segmentation of regions of interest. It is also voxel-based and therefore 
does not assume homogeneous regional radiotracer distributions for the tumor and/or 
surrounding background. 
Tumor delineation and parameters extraction 
For each patient, the tumor was identified on the baseline pretreatment PET images 
by an experienced nuclear physician. It was then delineated using the Fuzzy Locally 
Adaptive Bayesian (FLAB) algorithm (20, 24) on both the original (without PVE 
correction) and PVE corrected images. This segmentation approach has been shown 
to give both robust and reproducible functional volume delineations under variable 
image noise characteristics (25-26).  
The following parameters were subsequently extracted from each baseline image 
with or without correction for PVE: SUVmax, SUVpeak defined as the mean of SUVmax 
and its 26 neighbors (roughly corresponding to a 1cm ROI), mean SUV (SUVmean) 
within the volume, MATV, and TLG (determined by multiplying SUVmean with the 
corresponding MATV). 
Statistical analysis 
Pearson coefficients were used to estimate correlation between the image derived 
parameters, and paired t-tests were used to characterize the differences between 
uncorrected and corrected parameters. The correlation between response to therapy 
and each parameter was investigated using the Kruskal-Wallis test as a non-
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parametric statistic allowing the comparison of parameter distributions associated to 
each category of response (CR, PR and NR). This test does not assume normal 
distribution of variables and the computation of its statistic H is based on ranks 
instead of absolute values of variables (27). Regarding survival, for each considered 
parameter, Kaplan-Meier survival curves were generated (28) for which the most 
discriminating threshold value allowing differentiation of the groups of patients was 
identified using receiver operating characteristic (ROC) methodology (29). Prognostic 
value of each parameter in terms of overall survival was assessed by the log-rank 
test.  
The significance of the following factors (with or without correction) was tested: 
SUVmax, SUVpeak, MATV, SUVmean, and TLG. All tests were performed two-sided 
using the MedcalcTM statistical software (MedCalc Software, Belgium) and p values 
below 0.05 were considered statistically significant. 
RESULTS 
Impact of PVC on the image derived parameters 
The PVE correction had an impact on the images that can be assessed visually, with 
a higher contrast between the tumor and the surrounding tissues, as it can be seen in 
figure 1 and illustrated using profiles in figure 2. Table II provides the distributions of 
volumes and associated parameters measured in original and corrected images. 
MATV delineated on original images and these delineated on images corrected for 
PVE were highly correlated (r>0.998, CI 0.997-0.999, p<0.0001). However, MATV 
delineated on PVC corrected images were systematically smaller (p<0.001) by on 
average -10±5% (range -1.5 to -22.4%), which resulted in a mean volume difference 
of -4±3 cm3 (40±36 cm3 vs. 36±34 cm3). This is illustrated on two different tumors in 
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figure 3. There was no significant correlation between these differences and the PET 
lesion volumes (r<0.2, p>0.18).  
All primary lesions were detected by 18F-FDG PET and exhibited a rather high uptake 
with a mean SUVmax of 10±4. As expected, SUVpeak and SUVmean measurements 
were comparatively lower (8±3 and 6±2 respectively). All SUV measurements are 
summarized in table II. After iterative deconvolution, SUVmax, SUVpeak and SUVmean 
were 15±6, 10±4 and 7±3 respectively. All were significantly higher than non-
corrected values (p<0.05). SUVmax increased by 54±23% (range 18-157%) while the 
impact on SUVpeak and SUVmean was lower with a mean increase of 27±10% (range 
8-51%) and 28±11% (range 9-59%) respectively. Considering the PVC induced 
decrease of MATV (-10±5%) and increase of corresponding SUVmean (+28±11%), 
PVC resulted in significantly higher TLG values (+14±12%, range -2 to +50%) 
(p<0.0001).  
The increases of SUVmax and SUVpeak after PVC were not correlated with MATV 
(r<0.2, p>0.2), whereas the increase of SUVmean was inversely correlated with MATV 
(r=-0.79, p<0.0001), with higher increase observed for smaller volumes. 
Impact of PVC on the predictive and prognostic values 
25 patients were classified as PR, 11 were CR and 14 were NR (including stable and 
progressive disease). With a median follow-up of 60 months (range 10-84), the 
median overall survival was 12 months and the 1-year and 2-year survival rates were 
60% and 35% respectively. 10 patients were alive with no evidence of disease at the 
time of last follow-up, while 9 were alive with recurrent disease and 31 had died. 
Survival was significantly correlated with response, as overall survival was 24±15 
(median 21), 22±20 (median 14) and 9±4 (median 10) months for CR, PR and NR 
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respectively (p<0.01). Results concerning the prognostic and predictive value of all 
considered parameters with and without PVC are summarized in tables III and IV. 
Initial SUVmax whether corrected for PVE or not, was not predictive of response to 
therapy (p=0.2 and p=0.3 for SUVmax and SUVmax
PVC respectively) although CR tend 
to have smaller SUVmax (7.8±4.2 and 12.2±6.6 after PVC) than PR and NR (10.2±3.7 
and 10.3±3.8 for PR and NR respectively, 15.9±6.0 and 15.5±5.7 after PVC) (figure 
4A). SUVpeak led to slightly more differentiated groups of response without reaching 
statistical significance (p=0.08), with a mean value of 6.2±3.6 in complete 
responders, whereas both PR and NR were characterized by similar higher SUVpeak 
values (8.5±3.1 and 8.5±3.2 for PR and NR respectively). After PVC, the results 
using SUVpeak were similar with 7.8±4.4, 10.7±3.7 and 10.8±3.9 for CR, PR and NR 
respectively (p=0.1). The SUVmean measurements could not significantly predict 
response (p=0.07), and the differentiation between the three groups of response 
considered based on SUVmean was still not possible after PVC (p>0.14). 
None of the SUV measurements was a significant prognostic factor in the univariate 
analysis, despite a trend for longer survival associated with lower SUV (max, peak or 
mean). For instance, a SUVmax below a threshold of 8 or a mean SUV under 6.5 tend 
to be associated with a better outcome and a median survival of 20 vs. 13 months 
(p=0.3) and 16 month vs. 10 months (p=0.15) respectively. Similarly after PVC no 
threshold value could significantly differentiate groups of patients regarding their 
survival (see figure 5A-B). 
Contrary to SUV measurements with or without PVC, the parameters related to 
functional volume (MATV and TLG) allowed significant (p<0.0001) differentiation of 
the three response groups, and were significant prognostic factors (p<0.002), as 
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illustrated in figure 4C. No significant differences were found using the original or 
PVC corrected values. 
The parameter that allowed for the best differentiation of patients groups was the 
TLG (p<0.0001). CR were characterized by a TLG of 55±45g, whereas PR and NR 
had a TLG of 178±143g and 416±238g respectively. After PVC, the absolute values 
of each group rose to 62±45g, 200±155g and 437±249g for CR, PR and NR 
respectively, leading to the same discrimination between groups of response 
(p<0.0001). Although slightly less efficient than TLG, the use of MATV allowed a 
statistically significant differentiation of the three response groups (p<0.0001). Using 
the MATV values extracted from PVC images led to exactly the same discriminating 
power (p<0.0001). 
MATV and TLG were also good prognostic factors, with high MATV and TLG values 
being significantly associated with shorter survival with hazard ratios between 3 and 
4 (table III). A MATV above 85cm3 was identified as a predictor of poor outcome with 
a median survival of 6 months only vs. 20 months for patients with smaller MATV 
(p=0.0004) as illustrated in figure 5C. In addition, a MATV below 15cm3 was 
associated (p=0.009) with longer survival (49 months) than larger MATV (11 months). 
Similar results were obtained using the MATVs measured on the PVC corrected 
images, with a median survival of 20 months for patients with TVPVC below 80cm3 vs. 
10 months (p<0.002). Regarding TLG, a threshold of 260g was found to be a good 
discriminating factor for outcome (21 vs. 10 months, p=0.0012) whereas using PVC 
corrected TLG led to similar results with a slightly higher threshold (TLGPVC=280g, 21 





Our study investigated the impact of partial volume effects correction on the 
predictive and prognostic value of different parameters derived using the baseline 
pre-treatment PET images. Our results confirmed that PVE correction has a 
significant impact on quantitative SUV values with an average increase of above 50% 
for SUVmax, in agreement with previous studies (18-19), and lower increase (below 
30%) for SUVpeak and SUVmean. The lower increase observed for SUVpeak and 
SUVmean is related to the fact that the L-R deconvolution is a voxel-by-voxel process 
leading to enhancement of contrasts between sub-volumes within the MATV and 
both lower and higher voxels’ SUV values included in the averaging associated with 
the calculation of mean and peak SUV. PVC did not have a significant impact on the 
delineation of the MATV. Overall, MATVs delineated on the corrected images were 
only slightly smaller than those determined on the original images. The mean 
reduction of 10% was within the reproducibility limits of confidence intervals regarding 
tumor volume measurements on double baseline PET scans using FLAB (±30%) 
(26). This limited impact of PVC on MATV can be explained by the fact that PVE is 
dependent on tumor size and is more pronounced on small lesions (30). In our group 
of patients the tumors were rather large (40±30cm3) therefore the relative variation of 
volumes with respect to the entire volume is small. 12 (25%) of them had MATV 
around 10cm3 or smaller. In addition, the use of a robust delineation approach 
instead of threshold-based methods in various configurations of blur and noise (25, 
31) ensured a limited variability in the MATV delineation results between original and 
corrected images. 
As previously demonstrated (7, 12), MATV and TLG extracted from non corrected 
18F-FDG PET pre-treatment acquisitions had high clinical value. On the contrary, 
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none of the usual SUV measurements (max, peak or mean) considered in clinical 
practice was significantly associated with therapy response or survival, as also 
reported in the two largest available prospective trials (32-33). 
Regarding response to therapy prediction using SUVs, we found that PVE correction 
did not improve the already demonstrated low discriminating power of any of the SUV 
measurements considered (7). This can be explained by the combination of several 
factors. First, without PVE correction, the trend of low SUV being associated with 
better outcome may have been exaggerated by an underestimation of SUV, since 
complete responders had also smaller volumes in addition to low SUVmax. Secondly, 
after PVE correction all three response groups had increased SUVmax, but with still no 
significant difference between the groups. We have demonstrated that mean SUV 
increase after PVC was inversely correlated with TV (r=0.8, p<0.0001), smaller 
volumes being characterized by higher mean SUV increases after PVC compared to 
larger volumes. The mean SUV values within the MATV of partial or non responders 
were therefore increased by a smaller amount (+20±9%) than those within the MATV 
of complete responders (+34±13%) which were associated with smaller tumor 
volumes. The mean tumor SUVs of complete responders were therefore closer to the 
mean SUVs of partial and non responders after correction. Hence, the discriminating 
power of SUVmean was reduced by PVE correction. A similar trend was observed for 
SUVmax and SUVpeak, although it was less significant since their respective increase 
was not correlated to the MATV. Therefore PVC might have further reduced the 
clinical value of SUV measurements in this context. This effect has been previously 
suggested as a limitation to the prognostic value of SUVmax in early stage non small 
cell lung cancer (34). 
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Similar conclusions can be drawn from the results regarding the impact of PVC on 
the prognostic value of the SUV parameters. Indeed, as already demonstrated (12), 
extreme MATV values were significantly associated with longer or shorter overall 
survival for very small (49 months for MATV below 15 cm3 vs. 11 months) or very 
large MATV (8 months for TV above 85cm3 vs. 20 months) respectively. On the other 
hand, SUV measurements without correction cannot significantly differentiate 
between the patients with longer or shorter survival (p>0.05 for all SUV 
measurements) although a trend for longer survival was associated with lower SUVs. 
After correction, this differentiation was not significantly improved, because SUVs 
associated with the smaller volumes were closer to the SUVs associated with larger 
volumes. Therefore the discrimination was again reduced by PVC. To our knowledge 
there is no similar data available on the impact of PVC on SUV predictive value in the 
literature, but our results are in agreement with previous findings that demonstrated 
no significant changes in disease-free survival correlation between original and 
corrected SUVs in esophageal cancer using alternative less accurate methodologies 
for both PVE correction and functional volume segmentation (19).  
As previously demonstrated (7, 12), MATV and associated TLG values were good 
predictors of response (7) and independent prognostic factors of overall survival (12). 
After PVC the already high clinical value of MATV and TLG was not significantly 
altered. Considering the thresholds used to differentiate patient groups, there was no 
need for adjustment regarding MATV measurements since MATVs were not 
significantly modified by PVC. On the other hand, TLG thresholds needed to be 
adjusted, considering that PVC led to significantly increased mean SUVs and 
resulting TLG values. The determined threshold values for each parameter regarding 
prognosis or prediction of response were found using ROC analysis on the current 
 15 
patient cohort and would therefore require larger prospective studies in order to be 
validated. 
The rather large tumor volumes (40±30cm3) in our patients dataset might be 
considered as a limitation of this study, since partial volume effects are usually 
considered significant for volumes around or below 10 cm3 (30). Firstly, 25% of the 
tumors in this dataset were within this volume range. In addition, it should be noted 
that the shape of the primary esophageal lesions is not spherical but mostly 
cylindrical with a small diameter (<2cm) in the transaxial direction. Therefore 
esophageal lesions can be significantly affected by partial volume effects despite the 
overall large metabolic volumes, as can be seen in figure 2 for a lesion with MATV 
above 25 cm3. Finally, the patient population used in this study represents a typical 
clinical routine practice patient population and was not selected based on the overall 
primary MATVs. 
CONCLUSIONS 
The results of this study demonstrate that PVE correction does not add any value in 
parameters derived from metabolically active tumor volumes such as MATV and TLG 
measured on 18F-FDG PET baseline acquisitions. PVC did not alter the already 
demonstrated clinical value of both parameters as predictive factors of the response 
to concomitant radio-chemotherapy or as prognostic factors of overall survival in 
locally advanced esophageal cancer. Similarly, although PVC led to increases in all 
SUV measurements (max, peak or mean) considered in clinical practice, the 
corrected values were still not significantly associated with either therapy response or 
prognosis. Finally, our study is in agreement with previous investigations using 
simpler tools, showing limited interest of PVC in this specific context. However, the 
potential impact of PVE correction in other applications such as diagnosis or lesion 
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detectability remains to be evaluated. In addition, the value of PVC in patient follow 
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Figure 1: Illustration of the iterative deconvolution partial volume effects correction on a 
whole-body 18F-FDG PET image with (A) the original image and (B) the corrected image. 
Figure 2: Qualitative differences between original and corrected PET images of an 
esophageal lesion of MATV above 25 cm3 using profiles on axial, sagittal and coronal planes. 
Figure 3: Examples of FLAB delineation results (blue contours) on the original (left) and the 
corrected (right) PET images with (A) a large slightly heterogeneous MATV, (B) a MATV with 
a necrotic core, (C) a small homogeneous MATV. 
Figure 4: Examples of distributions of NR, PR and CR patients and associated Kruskal-
Wallis tests results: (A) SUVmax and SUVmax
PVC, (B) MATV and MATVPVC, (C) TLG and 
TLGPVC. 
Figure 5: Examples of Kaplan-Meier survival curves obtained using: (A) SUVpeak, (B) 
SUVpeak
PVC, (C) MATV. 
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Table captions 
Table I: Patient demographic and clinical characteristics 
Table II: Distributions of parameters with and without PVC. 
Table III: Kruskal-Wallis test results (H statistic and associated p value) for each parameter, 
with the ability to differentiate (p<0.05) each pair of response group among patients (CR 
complete responders, PR partial responders and NR non responders). 
Table IV: Univariate analysis results using Kaplan-Meier survival curves with the optimal 
threshold cutoff, associated hazard ratios (HR), 95% confidence intervals (CI) for HR, as well 
as the associated p value and median survival of each group. 
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Parameter Number of patients (%) 
Gender  
  Male 45(90) 
  Female  5(10) 
 
Age  
  Range 45-84 
  Median 69 
 
Site  
  Upper esophagus 13(26) 
  Middle esophagus 20(40) 
  Lower esophagus 17(34) 
 
Histology type  
  Adenocarcinoma 14(28) 
  Squamous cell carcinoma   36(72) 
  
  
Histology differentiation  
  Well differentiated 14(28) 
  Moderately differentiated 12(24) 
  Poorly differentiated 5(10) 
  Unknown 19(38) 
 
TNM Stage  
           T1 7(14) 
           T2 8(16) 
           T3 24(48) 
           T4 11(22) 
           N0 20(40) 
           N1 30(60) 
           M0 34(68) 
           M1 16(32) 
 
AJCC Stage  
  I  4(8) 
  IIA  8(16) 
 IIB  6(12) 
 III 16(32) 







Mean ± SD 
 
PVC 
Mean ± SD 
 
Highest SUV SUVmax 9.7 ± 3.9 14.9 ± 6.1  
Mean of SUVmax and its 26 neighbors SUVpeak 8.0 ± 3.3 10.1 ± 4.0 
Mean SUV within MATV SUVmean 5.8 ± 2.4 7.4 ± 3.1 
Metabolically active tumor volume (cm3) MATV 39.9 ± 36.1  36.2 ± 33.7 




Parameter H P 










SUVmax 3.6 0.17   no no no 
SUVmax
PVC 2.4 0.31 no no no 
SUVpeak 5.1 0.08  no no no 
SUVpeak
PVC 4.7 0.10 no no no 
SUVmean 5.5 0.07 no no no 
SUVmean
PVC 3.9 0.14 no no no 
MATV 20.7 <0.0001 yes yes yes 
MATVPVC 20.7 <0.0001 yes yes yes 
TLG 25.1 <0.0001 yes yes yes 









SUVmax 8 1.5 0.7 to 3.1 0.28 20 vs. 13  
SUVmax
PVC 11 1.6 0.7 to 3.2 0.26 20 vs. 13 
SUVpeak 7 1.4 0.7 to 2.8 0.31 16 vs. 10 
SUVpeak
PVC 9 1.8 0.9 to 3.6 0.11 20 vs. 11 
SUVmean 6.5 1.7 0.8 to 3.6 0.15 16 vs. 10 
SUVmean
PVC 7.5 1.7 0.8 to 3.5 0.12 20 vs. 10 
MATV 85 3.9 1.0 to 15.2 0.0004 20 vs. 6 
MATVPVC 80 3.4 0.9 to 11.7 0.0024 16 vs. 10 
TLG 260 2.9 1.2 to 6.8 0.0012 21 vs. 10 
TLGPVC 280 3.2 1.3 to 7.6 0.0004 21 vs. 10 
 






































































































Median survival 16 months
SUVpeak > 7























Median survival 20 months
SUVpeak
PVC > 9






















MATV < 85 cm3
Median survival 20 months
MATV > 85 cm3
Median survival 6 months
Hazard ratio 3.9
p = 0.0004
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